Inibace

Cilazapril, the active ingredient in Inibace, is an angiotensin‑converting enzyme (ACE) inhibitor presented as an oral tablet for oral use. It is prescribed to lower high blood pressure and to manage heart failure and post‑myocardial infarction ventricular remodeling in adult patients.

GNH USA supplies Inibace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Our distribution network ensures timely delivery and reliable product traceability across continents.

Cilazapril is used in cardiovascular conditions that involve the renin‑angiotensin‑aldosterone system. It helps control blood pressure and improve heart function.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent stroke and kidney damage. - Heart failure: lowers afterload and improves cardiac output, decreasing symptoms such as dyspnea and fatigue. - Post‑myocardial infarction ventricular remodeling: limits adverse structural changes in the heart muscle, reducing the risk of subsequent heart failure.

Cilazapril may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Dry cough: persistent, non‑productive cough often reported early in therapy. - Dizziness or light‑headedness: especially after the first doses or dose increases. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Hypotension: especially in volume‑depleted patients. - Elevated serum creatinine: mild rise indicating renal effect.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway, requiring immediate medical attention. - Severe neutropenia or leukopenia: marked reduction in white blood cells. - Hepatic dysfunction: jaundice or elevated liver enzymes. - Anaphylactic reaction: systemic allergic response. - Acute renal failure: sudden loss of kidney function. - Hyperkalemia: dangerously high potassium levels.

When prescribing Cilazapril, clinicians should observe several precautionary measures to ensure patient safety. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before initiation and during therapy. - Electrolyte surveillance: monitor potassium levels, particularly when combined with potassium‑sparing agents. - Pregnancy contraindication: avoid use in pregnancy (Category D) due to risk of fetal toxicity. - Caution with renal impairment: dose adjustment may be required in patients with reduced kidney function. - Drug‑induced cough evaluation: assess persistent cough and consider alternative therapy if severe. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Cilazapril can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use increases risk of renal impairment, hyperkalemia, and hypotension. - Lithium: concurrent use may raise lithium concentrations, leading to toxicity. - Potassium‑sparing diuretics or supplements: may cause severe hyperkalemia. - ACE inhibitor plus ARB therapy: dual blockade heightens risk of hypotension, renal dysfunction, and hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Thiazide diuretics: can enhance hypotensive response; monitor blood pressure. - Trimethoprim‑sulfamethoxazole: may increase serum potassium. - Antidiabetic agents: ACE inhibition can enhance insulin sensitivity, requiring glucose monitoring.